AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02314013
Drug: Cephalosporin + Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
Trial: NCT00941343
Drug: Alfuzosin (XATRAL® - SL770499)
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
Trial: NCT02920658
Drug: NAVS Naphthalan
RxNorm normalized name: naphthalene
DrugBank: 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid (DB01734)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02920658
Drug: 0.05% Betamethasone dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01584934
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
Trial: NCT00154102
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
Trial: NCT02787278
Drug: SP-8203 High dose
RxNorm normalized name: high-density polyethylene
DrugBank: SP-8203 (DB11670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
Trial: NCT02787278
Drug: SP-8203 Low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: SP-8203 (DB11670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
Trial: NCT02218164
Drug: Pegylated Interferon alpha-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
Trial: NCT02218164
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
Trial: NCT04183881
Drug: Brodalumab 210mg SC
RxNorm normalized name: brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 210 mg, subcutaneous dosing, every 2 weeks
Trial: NCT00428415
Drug: Tesofensine
RxNorm normalized name: Tesofensine
DrugBank: Tesofensine (DB06156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02448771
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02448771
Drug: Bazedoxifene
RxNorm normalized name: Bazedoxifene
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01691248
Drug: fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Trial: NCT00513214
Drug: XOMA 052
RxNorm normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Trial: NCT00336908
Drug: a combination of MCT, LCT , and Fish Oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265056
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.
Trial: NCT00867880
Drug: IVIb
RxNorm normalized name: PEMIVIBART
DrugBank: Pemivibart (DB18720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
Trial: NCT01669538
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379340
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00379340
Drug: Vincristine Sulfate Liposome
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00096395
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00096395
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02518113
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03443778
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marcaine 0.5% Injectable Solution
Trial: NCT03443778
Drug: Bupivacaine 0.5% , Dexamethasone
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% , Dexamethasone
Trial: NCT00242216
Drug: ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Trial: NCT00242216
Drug: ritonavir-boosted fosamprenavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Trial: NCT00004037
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00818480
Drug: YM155
RxNorm normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion
Trial: NCT00990886
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg once daily for 12 weeks
Trial: NCT04341090
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
Trial: NCT00658528
Drug: Rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
Trial: NCT00658528
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
Trial: NCT03665545
Drug: IMA950/Poly-ICLC
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMA950 mixed with Poly-ICLC administered subcutaneously
Trial: NCT03665545
Drug: IMA950/Poly-ICLC and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
Trial: NCT01067690
Drug: Indinavir in association with Vinblastina +/- Bleomicina
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
Trial: NCT00660699
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00660699
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00180050
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00593008
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
Trial: NCT00593008
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously every other week of each 28-day cycle.
Trial: NCT00876421
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg / 12 weeks
Trial: NCT00876421
Drug: ONO-8539
RxNorm normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose / 12 weeks
Trial: NCT03962829
Drug: mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants administrate one capsule of mCPP (30mg)
Trial: NCT00146471
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed
Trial: NCT00876421
Drug: ONO-8539
RxNorm normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium dose / 12 weeks
Trial: NCT01117610
Drug: Ropivacaine (epidural injection)
RxNorm normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
Trial: NCT00876421
Drug: ONO-8539
RxNorm normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: higher dose / 12 weeks
Trial: NCT01055964
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03352349
Drug: Terlipressinum
RxNorm normalized name: Terlipressinum
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
Trial: NCT00106197
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
Trial: NCT03320057
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
Trial: NCT04071600
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal
Trial: NCT00455052
Drug: XMT-1001
RxNorm normalized name: XMT-1001
DrugBank: XMT-1001 (DB06069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
Trial: NCT02456532
Drug: Zolpidem CR
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: six months of nightly zolpidem
Trial: NCT02456532
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01000337
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
Trial: NCT01000337
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
Trial: NCT00056147
Drug: denufosol tetrasodium (INS37217)
DrugBank: Denufosol (DB04983)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01762787
Drug: Cantharidin solution
RxNorm normalized name: cantharidin Topical Solution
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
Trial: NCT01762787
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
Trial: NCT00717093
Drug: Varenicline Tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Trial: NCT00527501
Drug: Travoprost/brinzolamide
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02606448
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infiltration of liposomal bupivacaine
Trial: NCT02606448
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivicaine was used in all femoral nerve blocks
Trial: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
RxNorm normalized name: Ticagrelor Tablets
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg single dose
Trial: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) administered without water
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg single dose
Trial: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg single dose
Trial: NCT02400333
Drug: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg single dose
Trial: NCT00875875
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
Trial: NCT02122172
Drug: afatinib dimaleate
RxNorm normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04151459
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use Metformin for 3 months to treat PCOS
Trial: NCT03922373
Drug: Group A: Benzonatate 100mg
DrugBank: Benzonatate (DB00868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Trial: NCT03922373
Drug: Group B: Benzonatate 200mg
DrugBank: Benzonatate (DB00868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Trial: NCT03922373
Drug: Group C: Benzonatate 400mg
DrugBank: Benzonatate (DB00868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
Trial: NCT00864318
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
Trial: NCT00864318
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
Trial: NCT00864318
Drug: Carboplatine
RxNorm normalized name: Carboplatine
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient
Trial: NCT00864318
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
Trial: NCT02555878
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
Trial: NCT02697045
Drug: Aripiprazole 400mg LAI
RxNorm normalized name: aripiprazole 400 MG
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 400mg, IM, Once a month
Trial: NCT01009567
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
Trial: NCT01009567
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive human albumin 20% infusion
Trial: NCT03235778
Drug: Felbinac Trometamol Injection
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Trial: NCT02750761
Drug: Tedizolid Phosphate (IV)
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/vial powder for injection
Trial: NCT02750761
Drug: Tedizolid Phosphate (oral suspension)
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Powder for oral suspension 20 mg/mL following reconstitution
Trial: NCT01800370
Drug: Hyperglycemia
RxNorm normalized name: Mifepristone 300mg Oral tablet [Cushing's Syndrome Hyperglycemia]
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
Trial: NCT01800370
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
Trial: NCT03642457
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 cc 0.5%